Urolog. pro Praxi, 2004; 2: 59-63

Prostatický specifický antigen a odvozené parametry

MUDr. Michael Pešl, MUDr. Libor Zámečník, MUDr. Viktor Soukup, prof. MUDr. Jan Dvořáček DrSc
Urologická klinika 1. LF UK a VFN Praha

Keywords: prostate specific antigen # sensitivity, specificity, velocity, density, doubling time.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pešl M, Zámečník L, Soukup V, Dvořáček J. Prostatický specifický antigen a odvozené parametry. Urol. praxi. 2004;5(2):59-63.

Nádorové markery jsou významnými pomocníky v diagnostice a při sledování aktivity onkologických onemocnění. Od počátku 80. let je k dispozici relativně velmi spolehlivý marker karcinomu prostaty v podobě prostatického specifického antigenu (PSA). Jeho sérová hladina je PSA považována za nejspolehlivější marker časného stadia onemocnění, které má největší šanci na vyléčení. Ve snaze zvýšit specificitu a senzitivitu se hodnotí jeho hladina ve vztahu k věku, objemu prostaty, stanovuje se volná frakce PSA a sleduje se rychlost nárůstu hladiny PSA v séru. Autoři v článku podávají přehled těchto odvozených parametrů a jejich význam pro detekci a sledování aktivity karcinomu prostaty.

PROSTATE SPECIFIC ANTIGEN AND DERIVED PARAMETERS

Tumour markers are important auxiliaries in the diagnosis and in monitoring the activity of oncological diseases. Urologists worldwide have since the beginning of the 80- quite reliable marker of prostate carcinoma available in the form of prostate specific antigen (PSA). Presently is a PSA serum level considered as the most reliable marker of an early stage of disease, which has the best chance for cure. In efforts to increase PSA specificity and sensitivity, the PSA level is referred to age, prostate volume, free fraction of PSA is defined and the velocity of PSA increase in serum is determined. Authors give in the article an overview of these derived parameters and of their importance for the detection and monitoring the activity of prostate carcinoma

1Urologická klinika VFN a 1. LF UK, Praha

2Katedra urologie IPVZ, Praha

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Benson MC, Whang IS, Pontuk A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol, 1992; 147: 815-816. Go to original source... Go to PubMed...
    2. Brawer MK, Aramburu EAG, Chen GL, et al. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol, 1993; 150: 369-373. Go to original source... Go to PubMed...
    3. Carter HB, Epstein JI, Chan DW, et al. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA, 1997; 277: 1456-1460. Go to original source...
    4. Carter HB, Pearson JD, Metter J, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA, 1992; 267: 2215-2220. Go to original source...
    5. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer: a new concept. Urol Clin North Am, 1993; 20: 665-665. Go to original source... Go to PubMed...
    6. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 1998; 279: 1542-1547. Go to original source... Go to PubMed...
    7. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 1994; 151: 1283-1290. Go to original source... Go to PubMed...
    8. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol, 1994; 152: 2031-2036. Go to original source... Go to PubMed...
    9. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ confined prostate cancer is increased through prostate specific antigen-based screening. JAMA, 1993; 270: 948-954. Go to original source...
    10. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA, 1995; 274: 1214-1220. Go to original source...
    11. Djavan B, Marberger M, Zlotta A, Schulman CC. PSA, f/t-PSA, PSAD, PSA-TZ, and PSA-velocity for prostate cancer prediction: a multivariate analysis [abstract]. J Urol, 1998; 159: 235-235. Go to original source...
    12. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA, 1995; 273: 289-294. Go to original source...
    13. Gao CL, Dean RC, Pinto A, et al. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol, 1999; 161: 1070-1076. Go to original source... Go to PubMed...
    14. Gao CL, Maheshwar S, Dean RC, et al. Blinded evaluation of reverse transcriptase-polymerase chain reaction prostatespecific antigen peripheral blood assay for molecular staging of prostate cancer. Urology, 1999; 53: 714-721. Go to original source... Go to PubMed...
    15. Ghavamian R, Blute ML, Bergstralh EJ, et al. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patiens undergoing radical retropubic prostatectomy. Urology, 1999; 54: 105-110. Go to original source... Go to PubMed...
    16. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol, 1997; 158: 326-37. Go to original source...
    17. Haese A, Huland E, Graefen M, et al. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol, 1999; 161: 1206-1211. Go to original source... Go to PubMed...
    18. Hara M, Inoue T, Koyanagi Y, et al. Immunoelectrophoretic studies of the protein components in human seminal plasma (especially its specific component). Nippon Hoigaku Zasshi, 1972; 26: 78-80.
    19. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate specific antigen concentrations. Urology, 1997; 50: 239-243. Go to original source... Go to PubMed...
    20. Chen YT, Luderer AA, Thiel RP, et al. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology, 1996; 47: 518-524. Go to original source... Go to PubMed...
    21. Ignatoff JM, Oefelein MG, Watkin W, et al. Prostate specific antigen reverse transcriptase-polymerase chain reaction assay in preoperative staging of prostate cancer. J Urol, 1997; 158: 1870-1875. Go to original source... Go to PubMed...
    22. Kalish J, Cooner WH, Graham SD. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology, 1994; 43: 601-606. Go to original source... Go to PubMed...
    23. Katz AE, Olsson CA, Raffo AJ, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology, 1994; 43: 765-775. Go to original source... Go to PubMed...
    24. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostatespecific antigen in a community-based population of healthy men. JAMA, 1993; 270: 860-864. Go to original source... Go to PubMed...
    25. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol, 1991; 145: 907-923. Go to original source... Go to PubMed...
    26. Olsson CA, de Vries GM, Buttyan R, Katz AE. Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol Clin North Am, 1997; 24: 367-378. Go to original source... Go to PubMed...
    27. Partin AW, Criley SR, Subong ENP, et al. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol. 1996; 155: 1336-1339. Go to original source... Go to PubMed...
    28. Patel A, Dorey F, Franklin J: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling time and log slope prostate specific antigen. J Urol., 1997; 158: 1441-1445. Go to original source... Go to PubMed...
    29. Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol, 1994; 152: 1826-1830. Go to original source... Go to PubMed...
    30. Pound CR, Partin AW, Eisenberg MA. Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 1999; 281: 1591-1597. Go to original source... Go to PubMed...
    31. Seaman E, Whang M, Olsson CA, et al. PSA density (PSAD): role in patient evaluation and management. Urol Clin North Am, 1993; 20: 653-663. Go to original source... Go to PubMed...
    32. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA, 1996; 276: 1309-1315. Go to original source...
    33. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol, 1994; 152: 1163-1167. Go to original source... Go to PubMed...
    34. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 1987; 317: 909-916. Go to original source... Go to PubMed...
    35. Šafařík L. Increased prostate cancer detection: the most efficient tools. BJU, 2002; 90: 190-190.
    36. Šafařík L, Novák K, Stolz J, Dvořáček J, Novák J. Does the Cindiny of prostatic intraepitelial neoplasia (PIN) influence the serum PSA and the PSA denzity? A prospective study of the influence of PIN findings on prostatic markers. Abstrect session 4, Central European Meeting. Hungary, Budapest 7-8 September 2001: 143-143.
    37. Šafařík L, Novák K, Stolz J, Novák J, Dvořáček J. Detekce karcinomu prostaty transrektální biopsií: porovnání senzitivity při odběru 8 a 10 vzorků a při opakované biopsii pro předchozí negativní výsledek. Čes. Urol., IV, 2000; 3: 24-24. In: Česká urologie. IV, 2000; 3: 24-24. 12. Kongres České urologické společnosti ČLS JEP a Slovenské urologické společnosti. ČR, Liberec 2000.
    38. Trapasso JG, DeKernion JB, Smith RB. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 1994; 152: 1821-1825. Go to original source... Go to PubMed...
    39. Vashi AR, Wojno KJ, Henricks W, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27. Go to original source... Go to PubMed...
    40. Vessella RL, Blouke KA, Stray JE, et al. The use of the polymerase chain reaction to detect metastatic prostate cancer in lymph nodes and bone marrow. Proc Am Assoc Cancer Res. 1992; 33: 396-396.
    41. Wang MZ, Gao ZW, He DL, Chen XF, He H, Wang WS, Nan XY. Age-specific reference ranges for serum prostate specific antigen in Chinese men. Zhonghua Yi Xue Za Zhi. 2003; 19: 1665-1667.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.